Waters Corporation reinvested in the protein characterisation technology producer through an oversubscribed round that will fund innovation and expansion.
US-based analytical instrument developer RedShift BioAnalytics completed an oversubscribed $18m series D round on Wednesday featuring laboratory equipment producer Waters Corporation.
RedShift has created a protein characterisation system for use in the development and production of protein-based therapeutics. It combines infrared technology and data analytics tools to track changes in protein structural attributes that had previously not been detectable.
The company has deployed production systems at three pharmaceutical companies and intends to put the series D proceeds into commercial growth…
